The success of our innovative drug candidates can benefit millions of cancer patients

After more than 20 years of research and hard work, our company has developed innovative technologies to overcome many of the challenges associated with polysaccharide drug conjugates. We have achieved significant breakthroughs in the fields of polysaccharide functionalization, position-specific taxane functionalization, and the synthesis of polysaccharide-based polymer-drug conjugates.

The first-in-class new drug candidate, CQ-0736, developed from the GlycoTDS™ platform, not only effectively targets the most aggressive RAS-driven pancreatic and lung tumors in vivo without observed toxicity in mice, but also shows strong potential in combination therapy with (pan) RAS inhibitors, CQ-0736 may help overcome the inherent resistance and limitations of these drugs.

In the diagram below, RMC-6236 is highlighted as a pan-RAS-ON inhibitor and is considered as a “world-class” drug candidate for RAS-driven cancers. Adagrasib, meanwhile, is an FDA-approved KRAS G12C inhibitor.